News Releases

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M.

The thyroid hormone receptor-beta ( THR- b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects Demonstrated favorable PK with low variability Dose responsively lowered lipid levels in study subjects Was

Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose dependent mean reductions of up to 2 log 10 IU/mL for HBV antigens Mean DNA reductions of up to 6.8 log 10 IU/mL No viral DNA breakthroughs in subjects

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is

November 16 Event to feature KOL perspective on Emerging HBV Therapies SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will report

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that an abstract for its capsid

Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025 SOUTH SAN FRANCISCO, Calif., Oct.

- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of ALG-097558    - First in human Phase 1 study evaluating single/multiple doses of ALG-097558 in